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Background:HRHPV genotypes when assayed collectively, achieve high sensitivity but low speciﬁcity for
the prediction of CIN2+. Knowledge of the speciﬁc genotypes in an infection may facilitate the use of HR
HPV detection in routine clinical practice.
Objectives: To compare the rate of HR HPV detection and the accuracy of CIN2+ prediction between
PapType test (Genera Biosystems) and other commercially available HR HPV assays, and to examine the
value of full HPV genotyping.
Study design: PreservCyt samples from 1099 women referred for abnormal cervical cytology were used.
CIN2+ was chosen as the primary end-point but CIN3+ was also evaluated. A hierarchy of HR HPV geno-
types was created using PPV and this was used to create 3 groups of genotypes with potentially different
management.
Results: The PapType assay has a speciﬁcity of 22.4% and a sensitivity of 94.6% for CIN2+ prediction.
Classiﬁcation into Groups A (HPV33 and HPV16, very highly predictive), B (HPV31, 18, 52, 35, 58, 51
highly predictive) and C (HPV68, 45, 39, 66, 56, 59, intermediate predictive) could double the speciﬁcity
(44.5%) but only slightly reduce the sensitivity for CIN2+ (91.5%) and CIN3+ (94.0%).
Conclusions: The PapType assay is a simple, reproducible and effective test for HR HPV detection and
genotyping. HPV 33 was found to have a very high PPV and should therefore be managed as for HPV16.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. . Background
Over 230 distinct papillomavirus genotypes have been identi-
ed based on nucleic acid sequence analysis and 179 are human
apillomaviruses [1,2]. 12–14 HR HPV genotypes are usually
ssayed collectively to achieve high sensitivity for predicting high
rade cervical lesions. However, this leads to a low speciﬁcity,
specially in young women [3–5]. As a result, individual geno-
ype detection (in particular HPV16 and HPV18), has been added to
ome commercial tests and algorithms for using these have been
roposed [6]. The value of full genotyping is not clear.
Here we evaluate PapType, a new semi-automated bead-based
ultiplex genotyping assay from Genera Biosystems capable of
dentifying 16 HPV genotypes individually (HPV6, 11, 16, 18, 31,
Abbreviations: HR HPV, high risk human papillomavirus; CIN2+ and/or CIN3+,
igh grade cervical intraepithelial neoplasia; PPV, positive predictive value.
∗ Corresponding author. Tel.: +44 02078823518; fax: +44 020 7882 3890.
E-mail address: j.cuzick@qmul.ac.uk (J. Cuzick).
1 Deceased.
ttp://dx.doi.org/10.1016/j.jcv.2014.02.002
386-6532 ©2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND li33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a single assay [7,8],
and assess whether the identiﬁcation of more HR HPV genotypes
could improve the triage of HR HPV positive women.
2. Objective
To compare the rate of HR HPV detection and the accuracy of
CIN2+ prediction between PapType assay and other commercially
availableHRHPV assays, and to examine the role of complete geno-
typing.
3. Study design
3.1. Study population
1099 women referred to the colposcopy clinics at the Hammer-
smith and St. Mary’s Hospitals for an abnormal screening smear
were included in this study (Predictors 2) [9]. Brieﬂy, two 20ml
PreservCyt samples were collected at the time of colposcopy and
1ml aliquotswere stored at 4 ◦C [9]. DNAextractionwas carried out
cense. 
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mmediately before the PapType assay. No PapType results were
btained for 32 women (3 had insufﬁcient sample volume and 29
amples yielded insufﬁcient DNA). In the remaining 1067 women,
here were 223 CIN3+ lesions (209 CIN3, 5 CGIN [high grade], 9
nvasive squamous carcinomas) and 131 CIN2 lesions. CIN3+ and
IN2 lesions (total = 354) were analysed together as CIN2+.
.2. Laboratory methods
.2.1. PapType high risk HPV detection and genotyping (Genera)
DNA extraction and puriﬁcation was carried out using the
2000 system (Abbott Molecular) and the RealTime DNA extrac-
ion reagents and protocol. Essentially, DNA was extracted from
00l PreservCyt samples, eluted in 100l water, of which 25l
as used for PCR. Detection of 14 HR and 2 LR HPV genotypes by
apType assay uses PCR ampliﬁcation using GP5+ and GP6+ con-
ensus primers. The PCR programme used was as follows:
94 ◦C for 15min; 48 cycles of 94 ◦C for 30 s, 44 ◦C for 1min
nd 72 ◦C for 1min; 72 ◦C for 5min then hold at 10 ◦C. Alkali
yosin light chain protein (MYL3) was used as human DNA con-
rol. Human DNA control and the test sample were ampliﬁed in
he same PCR. The amplicons were labelled during PCR (48 cycles)
ith red ﬂuorescent reporter dye Alexa Fluor® 647, converted to
ingle-strands by incubation with -exonuclease and captured by
ybridisation toHPVgenotype speciﬁc sequences (16HPV types +1
ontrol) individually immobilised on one of 17 PapType bead types
n a BODIPY® tetramethylrhodamine (TMR, yellow ﬂuorescence)
abelled silica bead (AmpasandTM) cocktail. The beads types were
dentiﬁed by a combination of bead diameter and discrete TMR lev-
ls andassayed for redﬂuorescence todetect thehybridisedanalyte
sing a ﬂow cytometer (FACSArray, BD). This allowed all genotypes
o be assayed in a single multiplex reaction.
Some cross reactivity was observed between HPV33 probe with
PV35 amplimers but not vice versa. This could have arisen due
o the HPV33 and the HPV35 speciﬁc probes sharing a homology
nvolving13nucleotides. Themanufacturer’s cut-off levelwas set at
50–710 ﬂuorescence units depending on the genotype (250 units
or HPV11, 16, 18, 31, 33, 35, 39, 45, 51, 56, 59 and 66; 350 units for
PV52, 58 and 68; 710 units for HPV6). This gave results showing
n excess of HPV33 low positives when HPV35 was also positive.
o correct for this, we raised the cut-off level of HPV33 to 1750
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units when and only when HPV35 was also detected while main-
taining the cut-off level of HPV35 at 250 units so that the number
of dual positive HPV33/35 cases was equal to the expected number
under the assumption that infection with HPV 33 and HPV35 were
independent events.
Fifty three samples were selected at random for repeat testing.
Perfect concordancewas found in45samples (84.9%), completedis-
cordance in 2 samples (3.8%) and partial discordance in 6 samples
(11.3%).
3.2.2. Other HPV assays
These are described in detail elsewhere [9].
3.3. Statistical methods
The main outcome measures were sensitivity, speciﬁcity and
positive predictive value (PPV). Conﬁdence intervalswere based on
binomial statistics. The PapType test was compared to other tests
(results from Ref. [9]) using the kappa statistic andMcNemar’s test
for discordant pairs. Added PPV for the new genotype was used to
optimise the sequential addition of new genotypes from the set of
14 HR HPV genotypes to create a hierarchy of genotypes, and the
results were plotted as a Receiver Operating Characteristic (ROC)
curve (cumulative sensitivity versus cumulative 1-speciﬁcity). The
risk of CIN2+ in relation to single versus multiple infection was
assessed by logistic regression. A forest plot was used to evalu-
ate the ability of the different HR HPV genotypes to identify CIN2+
infections, both in single and multiple infection contexts. Logistic
regression models and linear discriminant analysis were used to
assess the predictive ability of HR HPV genotype clusters on the
probability of developing CIN2+. All statistical analyses were car-
ried out using Stata 10.1 (StataCorp, USA) and R 2.15.0 software
packages (The R Foundation for Statistical Computing).
4. Results4.1. Diagnostic performance
With the 14 HR genotypes combined, PapType detected high
grade cervical lesions (CIN2+)with a sensitivity of 94.6%, speciﬁcity
y
.4 0.2 0.0                    
HC2
PapType
APTIMA
ealTime
Cobas
BD Viper LT
s A & B only
icated with 95%CIs. APTIMA (Hologic/Gen-Probe), BD Viper LT (Becton Dickinson),
ofer (Norchip), RealTime (Abbott).
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Fig. 2. ROC curve of cumulative sensitivity and speciﬁcity for CIN2+ (•—•) or CIN3+
(о - -о) when genotypes are ordered according to positive predictive value in
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f 22.4% and PPV of 37.7%. Its performance was similar to that of
ther DNA-based assays (Fig. 1 and Table 1, Ref. [5]).
.2. Genotype speciﬁc performance
PapType showed good agreement with other sensitive assays
or overall HR HPV genotype detection, PPV for CIN2+ (Table 1) and
etection of HPV16 or HPV18 (Table 2).
Genotypeswere selected tomaximise thePPVamong remaining
omen not having a genotype already selected (Fig. 2). The result-
ng orderwasHPV33, 16, 31, 18, 52, 35, 58, 51, 68, 45, 39, 66, 56 and
9. HR HPV genotypes were clustered into 3 hierarchical groups
Table 3). Group A (HPV33 and 16; PPV∼60%), group B (HPV31,
8, 52, 35, 58 and 51; PPV 20–40%) and group C (HPV68, 45, 39,
6, 56 and 59; PPV≤11%). HPV31 (PPV=39.5%) was intermediate
etween groups A and B but was included in group B because clus-
ering based on linear discriminant analysis gave a better ﬁt for this
ssignment.
Inclusion of genotypes fromgroups A and B only resulted in sen-
itivity for CIN2+ detection of 91.5% and a speciﬁcity of 44.5% (Fig. 1
nd Table 3). This sensitivity was higher than for p16 or for mild or
orse repeat cytology taken at colposcopy, but the speciﬁcity was
ot as high (Fig. 1). If the genotypes are ranked according to PPV
sing CIN3+ as the endpoint, HPV16 and HPV33 remain in Group A
ut are reversed in ranking. The exact order within Group B would
hange slightly and the rank order would be HPV31, 35, 52, 18, 39
added) and 51 with HPV58 now reclassiﬁed as Group C. The sen-
itivity of Groups A and B combined for CIN3+ is 94% based on the
IN2+ ranking and 95% based on the CIN3+ ranking (Fig. 2).
.3. CIN2+ risk associated with single or with multiple infections
ther than HPV16
When HPV16 was present, co-infection with other genotypes
id not confer additional risk (Fig. 3). The samewas true for HPV33
hen HPV16 was not present. The odds ratio for CIN2+ for mul-
iple rather than single infection with any HR HPV genotype in
omen without HPV16 was 1.61 (95%CI =1.07–2.41) (Fig. 3). In Ta
b
le
1
Po
si
ti
vi
ty
ra
A
ss
ay
Pa
p
Ty
p
e
B
D
V
ip
er
R
ea
lT
im
e
C
ob
as
a
A
PT
IM
A
a
Pr
eT
ec
tH
P
a
D
at
a
fr
o
J. Cuzick et al. / Journal of Clinical Virology 60 (2014) 44–49 47
Table 2
Comparison of PapType (Genera) with other HR HPV assays for the detection of HPV16, HPV18 or any HR HPV in <CIN2 and ≥CIN2 lesions. The P value was calculated with
McNemar’s test with the continuity correction.
Lesion grade HPV genotype Assaya Assay type Kappa index McNemar’s test for discordant pairs
PapType=+/−vs. −/+ OR (95%CI) P (2-tailed)
<CIN2 HPV16 RealTime DNA 0.93 8, 7 0.88 (0.27, 2.76) 1.0
BD Viper LT DNA 0.89 14, 10 0.71 (0.28, 1.73) 0.5
Cobas DNA 0.92 7, 12 1.71 (0.62, 5.14) 0.4
PreTectHPV-Proofer RNA 0.76 44, 2 0.05 (0.01, 0.17) <0.0001
APTIMA RNA 0.88 15, 8 0.53 (0.20, 1.34) 0.2
HPV18 RealTime DNA 0.95 3, 2 0.67 (0.06, 5.82) 1.0
BD Viper LT DNA 0.90 2, 9 4.50 (0.93, 42.80) 0.1
Cobas DNA 0.89 0, 12 ∞ 0.002
PreTectHPV-Proofer RNA 0.85 11, 3 0.27 (0.05, 1.03) 0.06
HPV18 or 45 APTIMA RNA 0.82 19, 5 0.26(0.08, 0.73) 0.008
AnyHR RealTime DNA 0.86 26, 9 0.35 (0.14, 0.76) 0.006
BD Viper LT DNA 0.86 15, 20 1.33 (0.65, 2.80) 0.5
Cobas DNA 0.83 17, 25 1.47 (0.76, 2.90) 0.3
PreTectHPV-Proofer RNA na na na na
APTIMA RNA 0.72 51, 22 0.43 (0.25, 0.72) 0.0009
CIN2+ HPV16 RealTime DNA 0.97 1, 4 4.00 (0.40, 196.99) 0.37
BD Viper LT DNA 0.95 1, 7 7.00 (0.90, 315.48 0.08
Cobas DNA 0.94 0, 11 ∞ 0.003
PreTectHPV-Proofer RNA 0.91 10, 5 0.50 (0.13, 1.61) 0.3
APTIMA RNA 0.96 1, 6 6.00 (0.73, 275.99) 0.1
HPV18 RealTime DNA 0.97 1, 1 1.00 (0.01, 78.50) 0.5
BD Viper LT DNA 0.94 1, 3 3.00 (0.24, 157.49) 0.6
Cobas DNA 0.94 0, 4 ∞ 0.1
PreTectHPV-Proofer RNA 0.91 4, 2 0.50 (0.05, 3.49) 0.7
HPV18 or 45 APTIMA RNA 0.82 7, 7 1.00 (0.30, 3.34) 0.8
AnyHR RealTime DNA 0.82 5, 2 0.40 (0.04, 2.44) 0.5
BD Viper LT DNA 0.79 2, 5 2.50 (0.41, 26.25) 0.5
Cobas DNA 0.80 1, 5 5.00 (0.56, 236.49) 0.2
PreTectHPV-Proofer RNA na na na na
APTIMA RNA 0.71 2, 7 3.50 (0.67, 34.53) 0.2
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TData from Ref. [9]. na, Norchip is not included since it assayed for 5 genotypes o
PTIMA (Hologic/Gen-Probe) and PreTectHPV-Proofer (Norchip).
eneral having a multiple infection conveyed no additional risk for
hoseHPVgenotypes inGroupB in the absence ofHPV16 (OR=1.44,
5%CI =0.90–2.30) but it did increase risk for those HPV genotypes
n Group C (OR=4.85, 95%CI =2.29–10.26). It would appear that
n multiple infections the genotype with the highest PPV largely
etermines the risk and the impact of the additional genotypes is
mall.
able 3
he classiﬁcation of HR HPV genotypes according to PPV for CIN2+.
Subgroup Genotype For the new type
N at risk CIN2+/HPV+ PPV
A HPV 33 1067 49/82 59.76
HPV 16 985 186/322 57.76
Subtotal 235/404 58.17
B HPV 31 663 32/81 39.51
HPV 18 582 17/58 29.31
HPV 52 524 13/53 24.53
HPV 35 471 8/32 25.00
HPV 58 439 7/34 20.59
HPV 51 405 12/58 20.69
Subtotal 89/316 28.16
C HPV 68 347 3/27 11.11
HPV 45 320 2/22 9.09
HPV 39 298 3/40 7.50
HPV 66 258 2/40 5.00
HPV 56 218 1/32 3.13
HPV 59 186 0/7 0.00
Subtotal 11/168 6.55
Total 335/888 37.73pType (Genera), BD Viper LT (Becton Dickinson), RealTime (Abbott), Cobas (Roche),
5. Discussion
The PapType assay described here detects 14 individual HR HPV
genotypes in a single assay and provides a simple, reproducible
and relatively high throughput semi-automated genotyping test
which takes approximately 9h of hands-on time for each run of
91 DNA samples. PapType has the potential for full automation
Cumulative
CIN2+/HPV+ PPV Sensitivity Speciﬁcity
49/82 59.76 13.84 95.37
235/404 58.17 66.38 76.30
267/485 55.05 75.42 69.42
284/543 52.30 80.23 63.67
297/596 49.83 83.90 58.06
305/628 48.57 86.16 54.70
312/662 47.13 88.14 50.91
324/720 45.00 91.53 44.46
327/747 43.78 92.37 41.09
329/769 42.78 92.94 38.29
332/809 41.04 93.79 33.10
334/849 39.34 94.35 27.77
335/881 38.02 94.63 23.42
335/888 37.73 94.63 22.44
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Fig. 3. Odds ratio for CIN2+ for multiple versus single type infection. For all individ-
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Ethics approvalal genotypes except HPV16, themultiple infections considered are those which do
ot include HPV16. There were no CIN2+ lesions with single HPV59 infection.
n a convenient microtitre format with full objective quantitative
eadout.
The diagnostic performance and genotyping accuracy of the
apType assay were found to be comparable to other assays using
ell documented routine clinical samples (Fig. 1, Tables 1 and 2).
wo type speciﬁc ﬁndings were of particular interest. First, HPV18
anked 4th and HPV45 ranked only 10th in risk for CIN2+. HPV18
onsistently ranks 2nd for cancer risk but much lower for high
rade CIN [10]. The lower ranking of HPV45 is similar to the rank-
ng order of 9th for CIN3+ in the ATHENA trial for CIN3+ based
n the Linear Array assay [11], but is in contrast to in 3rd place
anking in risk for cervical cancer worldwide [12]. In our study
opulation, the number of HPV45 positive lesions was too small
n=22) to have sufﬁcient statistical power to fully evaluate this,
ut its position in the risk hierarchy needs further evaluation.
PV18 and 45 have been consistently related to adenocarcinoma
nd low PPV for CIN2+. Persistent positivity of these 2 genotypes
ay indicate a lesion not easily visible by colposcopy and suggests
urther investigations higher in the endocervical canal. This may
e a reasonable justiﬁcation for genotyping them despite their low
PV. Secondly, HPV33 was associated with a PPV for CIN2+ and
IN3+ as high as HPV16 and substantially more predictive than
PV18 and other genotypes. This has been reported previously
13–18], but its signiﬁcance has not been fully recognised. Our
esults suggest that the oncogenic status of HPV33 should be ele-
ated and it should be assayed for in addition to HPV16 and HPV18
s in current practice. Similarly, HPV33 should also be targeted
y future HPV vaccines. PapType detected 7 samples positive for
oth HPV33 (at the raised cut-off value of 1750 units) and HPV35.
he median HPV33 signal was 3237, well above the raised cut-off
alue. Themanufacturer estimates that theHPV33probe signal due
o cross-reactivity with HPV35 amplimer is of the order of 30%
f the HPV35 probe signal. If this is the case, 5 of the 7 samplesVirology 60 (2014) 44–49
had an HPV33 signal far in excess of what could be attributable
to HPV35 and are therefore considered true positives for HPV33.
In this group, there are 2 high grade lesions. In the remaining 2
samples, the HPV33 signal might have been attributable to the
presence of HPV35. Neither of these lesions were high grade. A
full exploration of this cross reactivity would require a dilution
experiment with clones of HPV 33 and 35 which we have not yet
done.
As far asweareaware, this is theﬁrst reportwhichdemonstrates
a diagnostic classiﬁcation of HR HPV genotypes by sequential max-
imising of PPV which could facilitate the triage of women at risk
of CIN2+. Our results suggest that Group A (HPV16 and HPV33) has
the highest risk of being associatedwith high grade CIN and require
the most aggressive management [19–21]. Group B includes 6 fur-
ther genotypes (HPV31, 18, 52, 35, 58, 51) and also has a high PPV
for disease, but referral would probably also depend on the degree
of cytologic abnormality, or the existence of other risk factors such
as p16 positivity. The remaining 6 ‘high risk’ genotypes (68, 45, 39,
66, 56, 59) clearly carry a lower risk of disease with a PPV of only
6.5%, although they are still responsible for an additional 3.1% of
CIN2+ in this study and 6% of all cancers in Europe [10]. Here colpo-
scopic referral probably needs to be based on additional evidence of
persistence, high grade cytological abnormality or other risk factor
(e.g. p16).
Our genotype grouping also provided additional insight into
multiple infections with HR HPV, which are common in women
referredwith abnormal cytology. Previously, twomodels havebeen
proposed to attribute disease risk [22]. The “proportional model”
accords equal risk to individual genotypes in each multiple infec-
tion. The “hierarchical model” attributes the risk to the genotype
most frequently found in multiple infections. Neither of these
models takes the varying oncogenic potential of individual HPV
genotypes into account. In this study, we found that risk of high
grade disease in women with multiple infections can be assessed
by the single genotype present with the highest PPV (Table 3). This
is consistent with the observation that multiple infection with HR
HPV genotypes per se does not add to the risk of high grade CIN
beyond the risk associated with the highest risk single infection
[3].
The results obtained here are from a referral population with
abnormal cytology.Webelieve our conclusions regarding the geno-
type hierarchy are likely to also hold for a screening population, but
this remains to be established and validated in such a population.
Our collection and aliquotting procedures were also different from
those which would be used in routine practice, but this is unlikely
to affect our ﬁndings.
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